YD Bio (YDES) Receivables (2024 - 2025)
YD Bio's (YDES) quarterly Receivables came in at $459.0 billion in Q4 2025, up 343.46% year-on-year from $103.5 billion in Q4 2024, and up 452545497.95% on a QoQ basis from $101430.0 in Q2 2025.
YD Bio (YDES) Receivables (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Receivables data on file, last reported at $459.0 billion in Q4 2025.
- On a quarterly basis, Receivables rose 343.46% year-over-year to $459.0 billion in Q4 2025; TTM through Dec 2025 was $459.0 billion, a 343.46% increase from a year earlier, with the FY2025 full-year figure at $459.0 billion, up 343.46% from the prior year.
- Receivables for Q4 2025 stood at $459.0 billion, up from $101430.0 in the prior quarter.
- Over the last five years, Receivables for YDES reached as high as $459.0 billion in Q4 2025 and fell as low as $101430.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 4.97 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 938.02 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | 459.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 459.02 Bn |
| Jun 30, 2025 | 101,430.00 |
| Dec 31, 2024 | 103.51 Bn |